source
- Kymera Therapeutics to unveil mid‑stage eczema trial data, aiming to challenge DupixentKymera Therapeutics, a Massachusetts‑based biotech, is set to release data from its mid‑stage clinical trial of KT‑621 in eczema before the end of 2026. The trial results are being closely watched…
- FDA policy allowing compounding of unapproved peptides raises safety and development concernsThe Department of Health and Human Services recently approved the compounding of six peptide products that have not received FDA approval. This move expands the list of bulk substances that traditi…